• 1
    Egger M, May M, Chêne G et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 119129.
  • 2
    Sterne JAC, Hernán MA, Ledergerber B et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005; 366: 378384.
  • 3
    Sterne JA, May M, Costagliola D et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373: 13521363.
  • 4
    Sabin C. AIDS events among individuals initiating HAART: do some patients experience a greater benefit from HAART than others? AIDS 2005; 19: 19952000.
  • 5
    Kitahata MM, Gange SJ, Abraham AG et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360: 18151826.
  • 6
    Severe P, Juste MA, Ambroise A et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 2010; 363: 257265.
  • 7
    Emery S, Neuhaus JA, Phillips AN et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008; 197: 11331144.
  • 8
    Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, 2011.
  • 9
    World Health Organization. Rapid Advice: Antiretroviral therapy for HIV infection in adults and adolescents, 2009.
  • 10
    Mills EJ, Bakanda C, Birungi J et al. Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda. AIDS 2011; 25: 851855.
  • 11
    Braitstein P, Brinkhof MW, Dabis F et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367: 817824.
  • 12
    Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008; 22: 18971908.
  • 13
    Castelnuovo B, Manabe YC, Kiragga A, Kamya M, Easterbrook P, Kambugu A. Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort. Clin Infect Dis 2009; 49: 965972.
  • 14
    Ministry of Health, Uganda. National Antiretroviral Treatment and Care Guidelines for Adults, Adolescents, and Children, 2008.
  • 15
    Ministry of Health, Uganda. National Antiretroviral Treatment and Care Guidelines for Adults, Adolescents, and Children, 2009.
  • 16
    World Health Organization. Treatment of Tuberculosis Guidelines, 2010.
  • 17
    Hermans SM, Kiragga AN, Schaefer P, Kambugu A, Hoepelman AIM, Manabe YC. Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan Africa. PLoS ONE 2010; 5: e10527.
  • 18
    Muwanga A, Easterbrook P, Schaefer P et al. Losses to Follow-up in a Large ART Program in Uganda. Conference of Retroviruses and Opportunistic Infections. Boston, MA, February 2008 [Abstract 840].
  • 19
    Keiser O, Anastos K, Schechter M et al. Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health 2008; 13: 870879.
  • 20
    Cornell M, Grimsrud A, Fairall L et al. Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. AIDS 2010; 24: 22632270.
  • 21
    Boulle A, Van Cutsem G, Hilderbrand K et al. Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS 2010; 24: 563572.
  • 22
    Wools-Kaloustian K, Kimaiyo S, Musick B et al. The impact of the President's Emergency Plan for AIDS Relief on expansion of HIV care services for adult patients in western Kenya. AIDS 2009; 23: 195201.
  • 23
    Mulissa Z, Jerene D, Lindtjørn B. Patients present earlier and survival has improved, but pre-ART attrition is high in a six-year HIV cohort data from Ethiopia. PLoS ONE 2010; 5: e13268.
  • 24
    The Global Fund to Fight AIDS, Tuberculosis and Malaria. Annual Report. 2005.
  • 25
    Geng EH, Bwana MB, Kabakyenga J et al. Diminishing availability of publicly funded slots for antiretroviral initiation among HIV-Infected ART-Eligible patients in Uganda. PLoS ONE 2010; 5: e14098.
  • 26
    Tuboi SH, Schechter M, McGowan CC et al. Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the Caribbean. J Acquir Immune Defic Syndr 2009; 51: 615623.
  • 27
    Tuboi SH, Brinkhof MW, Egger M et al. Discordant responses to potent antiretroviral treatment in previously naive HIV-1-Infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration. J Acquir Immune Defic Syndr 2007; 45: 5259.
  • 28
    Babigumira JB, Castelnuovo B, Stergachis A et al. Cost effectiveness of a pharmacy-only refill program in a large urban HIV/AIDS clinic in Uganda. PLoS ONE 2011; 6: e18193.
  • 29
    Brinkhof MW, Egger M, Boulle A et al. Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis 2007; 45: 15181521.
  • 30
    Manabe YC, Breen R, Perti T, Girardi E, Sterling TR. Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy. J Infect Dis 2009; 199: 437444.
  • 31
    Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005; 19: 21092116.
  • 32
    Hanson DL, Chu SY, Farizo KM, Ward JW, Adult and Adolescent Spectrum of HIV Disease Project Group. Distribution of CD4+ T lymphocytes at diagnosis of acquired immunodeficiency syndrome – defining and other human immunodeficiency virus – related illnesses. Arch Intern Med 1995; 155: 15371542.
  • 33
    Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS ONE 2009; 4: e5790.
  • 34
    Egger M, Spycher BD, Sidle J et al. Correcting mortality for loss to follow-up: a nomogram applied to antiretroviral treatment programmes in sub-Saharan Africa. PLoS Med 2011; 8: e1000390.